Vaginal = Local Only?
That’s a Myth.

It absorbs into your whole body.

Vaginal hormone therapy bypasses the liver and delivers hormones systemically—not just locally.

  • Markedly enhances systemic bioavailability by avoiding first-pass hepatic metabolism
  • Near-complete absorption of estradiol and progesterone
  • Far exceeds oral (10–20%) and topical (3–20%) absorption rates
  • Results in more consistent serum hormone levels and better symptom control

It’s clinically more effective.

Vaginal delivery ensures stable, targeted hormone levels—leading to better outcomes.

  • Delivers a more stable hormone profile than oral or topical routes
  • Reduces hormonal fluctuations that trigger side effects
  • Improves patient ease of use with direct application
  • Recognized for superior symptom relief across energy, mood, libido, and sleep

It’s one of the safest routes available.

Vaginal hormone therapy avoids systemic risks by staying out of the liver.

  • Doesn’t increase clotting factors or stroke risk
  • Doesn’t elevate estrone levels
  • Bypasses hepatic metabolism entirely
  • Backed by over 50 clinical trials showing controlled, safe absorption through the vaginal mucosa

It protects your uterine lining.

Vaginal progesterone delivers local endometrial protection without unnecessary systemic exposure.

  • Uses the “first uterine pass effect” to concentrate progesterone at the endometrium
  • Enhances protection when paired with estradiol therapy
  • Avoids the reduced bioavailability and side effects of oral progesterone
  • Provides a more predictable progestogenic effect with minimal systemic impact
  1. Eva Sanchez Armengol, et al. Exploring the potential of vaginal drug delivery: innovations, efficacy, and therapeutic prospects. Journal of Pharmacy and Pharmacology, 2025; rgaf045.
  2. The North American Menopause Society. The 2022 hormone therapy position statement: no news is good news. The Journal of The North American Menopause Society, Vol. 29, No. 7, pp. 767–794
  3. Nappi, Rossella E. The 2022 hormone therapy position statement of The North American Menopause Society: no news is good news. The Lancet Diabetes & Endocrinology, Volume 10, Issue 12, 832–834.
  4. Dragoman, M., Petrie, K., et al. Pharmacokinetics of ethinyl estradiol and etonogestrel during extended use of a contraceptive vaginal ring. Contraception, Volume 86, Issue 3, 291–292.
  5. Yu Xin, et al. Uterine first-pass effect: Unlocking the potential of vaginally administered ritodrine-loaded drug delivery. European Journal of Pharmaceutical Sciences, Volume 204, 2025, 106945.
  6. American College of Obstetricians and Gynecologists (ACOG). Postmenopausal Estrogen Therapy Route of Administration and Risk of Venous Thromboembolism.
  7. Mitchel CM, Larson JC, Crandall CJ, et al. Association of Vaginal Estradiol Tablet With Serum Estrogen Levels in Women Who Are Postmenopausal: Secondary Analysis of a Randomized Clinical Trial.
JAMA Network Open. 2022;5(11):e2241743.
  8. Tourgeman, David E., et al. Serum and tissue hormone levels of vaginally and orally administered estradiol.
American Journal of Obstetrics & Gynecology, Volume 180, Issue 6, 1480–1483.
  9. Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens.
Menopause (New York, N.Y.) 2020 Mar;27(3):361–370.
  10. Wu Guolan, et al. Pharmacokinetic Properties of Three Forms of Vaginal Progesterone Administered in Either Single or Multiple Dose Regimen in Healthy Postmenopausal Chinese Women. Frontiers in Pharmacology, 2017.
  11. Packaging Label: Crinone® 4% and Crinone® 8% – FDA
  12. Stanczyk, Frank Z., Paulson, Richard J., Roy, Subir. Percutaneous administration of progesterone: blood levels and endometrial protection. The Journal of The North American Menopause Society, Vol. 12, No. 2, pp. 232–237.
  13. Levine, Howard, et al. Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertility and Sterility, Volume 73, Issue 3, 516–521.
  14. Srikrishna, S., Cardozo, L. The vagina as a route for drug delivery: a review.
International Urogynecology Journal 24, 537–543 (2013).
  15. Drug Packaging Label: Etonogestrel and Ethinyl Estradiol Vaginal Ring.
  16. Cicinelli, Ettore, et al. “First uterine pass effect” is observed when estradiol is placed in the upper but not lower third of the vagina. Fertility and Sterility, Volume 81, Issue 5, 1414–1416.
  17. Mary Beth Dorr, Anita L. Nelson, Philip R. Mayer, Radhika P. Ranganath, Paul M. Norris, Eileen C. Helzner, Richard A. Preston. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertility and Sterility, Volume 94, Issue 6, 2010, Pages 2365–2368.
  18. Sriprasert I, Mert M, Mack WJ, Hodis HN, Shoupe D. Use of oral estradiol plus vaginal progesterone in healthy postmenopausal women. Maturitas, 2021 Dec;154:13–19.
  19. Howard N., et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol for the ELITE Research Group. New England Journal of Medicine, 2016;374:1221–1231.
close
play
pause